BofA analyst Jason Zemansky lowered the firm’s price target on Keros Therapeutics (KROS) to $32 from $33 and keeps a Buy rating on the shares.

The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Retired Worcester firefighter Mark Stomski died on Sunday due to complications from injuries he sustained before his 2008 ...

If you suddenly feel short of breath and a bit anxious, it might be something called "dyspnea." Let's dive into what the ...

Cannabis dabbing, an increasingly popular way to consume highly concentrated THC, has been linked to pulmonary and neurologic ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

US clinical-stage pharma Keros Therapeutics today announced that it has voluntarily halted all dosing in the TROPOS trial, a ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Shares of Keros Therapeutics (KROS) plunged nearly 20% in premarket trading on Wednesday, poised to hit an all-time low after ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...